Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

BACKGROUND AND OBJECTIVE: To determine the effectiveness and direct medical costs of treat-and-extend (TAE) intravitreal bevacizumab (IVB) for the treatment of branch retinal vein occlusion (BRVO)-associated macular edema (ME). PATIENTS AND METHODS: Retrospective chart review of 52 consecutive patients diagnosed with BRVO-associated ME treated with IVB using a TAE protocol. RESULTS: Mean change in logMAR vision was -0.30 (P < .001), and mean change in central macular thickness was -244.0 μm (P < .001). The mean number of injections was 8.2 (95% CI; 7.8 to 8.6). The yearly average direct cost of the TAE regimen was calculated to be $2,580.26 per patient. CONCLUSION: Treatment of BRVO-associated ME with IVB using a TAE regimen resulted in similar visual outcomes and number of intravitreal injections as did as-needed treatment with 0.5 mg ranibizumab conducted in phase 3 trials but with fewer visits and lower annual medical costs.

Original publication




Journal article


Ophthalmic Surg Lasers Imaging Retina

Publication Date





212 - 216


Aged, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized, Bevacizumab, Female, Health Care Costs, Humans, Intravitreal Injections, Macular Edema, Male, Middle Aged, Retinal Vein Occlusion, Tomography, Optical Coherence, Treatment Outcome, Vascular Endothelial Growth Factor A, Visual Acuity